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ferent patient selection. We selected patients with RA who had taken at 
least one conventional 2nd line agent previously. The mean number of 2nd 
line agents per patient was 3, and only a minority had taken azathioprine 
and methotrexate (in 1990 in The Netherlands these were still 2nd line 
agents “at the top of the pyramid”) or used corticosteroids at the start of the 
study. This might indicate a patient group with relatively mild disease com­
pared to the patient group in Flipo and Reigncau’s study. In our opinion, 
patients with milder disease have less chance of developing unacceptable 
nephrotoxicity and/or hypertension, and these adverse events seriously 
influenced the discontinuation rate in Flipo and Reigneau’s study.
It is therefore questionable whether it is wise to limit the use of CyA 
only to patients with failure of most conventional 2 nd line agents (includ­
ing methotrexate), as has been ordered by registration authorities in a num­
ber of countries. We feel that CyA is safe in patients with RA provided that 
renal function and blood pressure are closcly monitored and dose titrations 
according to the guidelines are immediately implemented. Such meticulous 
followup should include a kidney biopsy in case of progressive increa.se of 
scrum creatinine in the long term, especially if continuation of CyA is con­
sidered clinically desirable.
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Evaluation of Disease Activity in Rheumatoid Arthritis and 
Other Arthritides Using ""’Technetium Labeled Nonspecific 
Human Immunoglobulin
To the Editor:
We read with interest the article by Jamar, et cil. The scintigrams 6 h after 
intravenous (iv) injection of  555 mBq WmTc IgG were subjectively scored 
on a 0-3 scale where 0 = no uptake; 1 = faint uptake; 2 = definite uptake, 
and 3 = marked uptake. The scores of synovial uptake correlated signifi­
cantly with systemic variables of inflammation1. The authors maintain that 
methods commonly used to assess joint inflammation are rather subjective 
and observer-dependent and that no available radiopharmaceutical has 
proven entirely satisfactory to evaluate synovitis. They claim that WmTc-fgG 
scintigrams can objectively determine joint activity. However their scinti­
grams are scores on an arbitrary scale and therefore this method is subjec­
tive.
In their discussion the authors mentioned that the use of a semiquLimi­
tative index for assessing joint activity appeared technically unpractical 
(background subtraction, large vessel capacity, small size of some joints, 
and limited spatial resolution of the gamma camera). IJi;mTc*pertechnetate 
(99mTc04) uptake in the joint after iv injection of 99mTc04 (7 MBq) has 
been found to be a valuable objective variable of joint inflammation2'5. In 
this method a simple collimated sodium-iodide crystal (probe) is used. An 
excellent to good correlation was found between the results of the ,;y,nTc- 
pertechnetate uptake and different clinical variables of joint inflammation. 
Reproducibility was good. Radiopharmaceutical uptake in the joint can be 
measured shortly after the iv injection1. The t,,)mTc04 uptake technique has 
proven to be useful in the diagnosis of doubtful arthritis and for evaluation 
of the effect of local and systemic therapy in inflammatory activity of the 
joint'’.
Radiodiagnostic methods to assess synovial inflammation most likely 
determine all the vascular changes (vascular proliferation, vasodilatation, 
vascular congestion, and endothelial lesions) induced by inflammation. The 
main advantage of external direct counting of joints in comparison with 
00|1'Tc-lgG scintigraphy of the joints is the lower dosage of 0<)mTc. In addition 
objective quantitation may be less difficult, the method is faster, relatively
simple, and inexpensive. The distribution o f  the radiopharmaceutical in the 
joint recorded on the scintigraph can give local information, but this is not 
relevant for measuring the severity of the disease activity.
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Drs. Jamar and Manicourt reply
To the Editor:
We thank Dr. Boerbooms and Buijs for their comments on our paper’. It 
was not our aim to quantify local synovitis, for several, mainly practical 
reasons. The word “activity” in our title should be understood widely as 
both extent and severity. We agree with Boerbooms and Buijs that, for 
assessing the activity o f  knee joints, the simple collimated sodium iodide 
crystal probe is more objective than our visual scoring system2. However, 
this statement calls for further comment. (I)  Although we use such a probe 
on a regular basis, (especially for hematological studies), this equipment is 
not available in the majority o f  nuclear medicine ccnters. Thus, this proce­
dure is limited to certain centers, whereas ours requires basic nuclear med­
icine equipment, i.e., a gamma camera which is widely available. (2) As 
each probe has its own physical characteristics, (especially with regard to 
geometry), normal quantitative values have to be established in each cen­
ter. (3) Although the radiation to patients using 7.4 mBq (200 pCi) ,WmTc- 
pertechnetate is much less than with 555 mBq WmTc-human immunoglobu­
lin, such a small dose does not allow whole body scanning and is unpracti- 
cable for assessing the extent o f  arthritides such as in rheumatoid arthritis.
(4) Boerbooms, et al have rightly restricted use o f  their method to the study 
of the knee, i.e., a large peripheral joint. It is indeed unlikely their probe 
method can accurately explore synovitis either in small peripheral joints, 
such as the hands, or in large and more axial joints, such as hips and shoul­
ders. In contrast, human immunoglobulin scintigraphy can readily and 
accurately detect synovitis in small peripheral joints and in large axial 
joints as well. Further we believe that the method proposed by Boerbooms 
and Buijs is perfectly suitable to assess the effect of local therapy, which 
was not the aim of our study.
Last, but not least, we are suiprised by their choice of free ,,<)mTc- 
pertechnetate as the tracer. Although this radiopharmaceutical offers 
several advantages, especially with regards to availability and simplicity of 
its use, it has not been used widely for imaging aseptic joint disorders. 
Indeed it has several drawbacks: (1) in contrast to lJ,,mTc-human 
immunoglobulin, it is not an inflammatory agent and its use in arthritis is
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purely empirical. (2) Normal synovium can be faintly visualized and the 
uptake by abnormal joints is less striking than the uptake of ,w,"Tc-human 
immunoglobulin. (3) Accordingly, the interpretation of abnormal images 
requires much more experience than does imaging with '""Tc-human 
immunoglobulin.
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Pancytopenia Related Eosinophilia in Rheumatoid Arthritis
To the Editor:
The case report by Bruyn, et al' states that eosinophilia has not been 
observed in other drug induced pancytopenias in patients with rheumatoid 
arthritis (RA). The authors further suggest that this could be a specific phe­
nomenon associated only with methotrexate (MTX), Their references 
include mention of penicillamine as a drug not associated with eosinophil­
ia in this context.
Apparently the authors overlooked an earlier paper describing 2 
patients who developed neutrophilic agranulocytosis and eosinophilia dur­
ing treatment with penicillamine5, in one case, eosinophilia was present 
only in the marrow, but in the 2nd case, there was eosiniphilia in both mar­
row and peripheral blood, with values as high as 30% in the recovery phase. 
Because of this the term agranulocytosis was qualified as neutrophilic 
agranulocytosis, since the eosinophils were not only spared, but actually 
increased. There is nothing unique about the ability o f  MTX to induce this 
phenomenon.
College of Physicians and Surgeons 
of Columbia UniversiLy,
New York, NY, USA.
Israeli A. Jaffe, MD,
R E F E R E N C E S
1. Bruyn GAW, Velthuysen E, Joosten P, Houtman PM: Pancytopenia 
related eosinophilia in rheumatoid arthritis: A specific methotrexate 
phenomenon? J Rheumatol 7995;22:1373-6.
2. Corcos JM, Soler-Bechara J, Mayer K, Freyberg R, Goldstein R, 
Jaffe I: Neutrophilic agranulocytosis during administration of 
penicillamine. JAMA 1964; 189:265-8.
Dr. Bruyn, et al reply
To the Editor:
Wc appreciate the interest shown in our paper1. In his letter, Jaffe mentions 
an article he and his colleagues published in 1964 on 2 patients with 
rheumatoid arthritis treated with D-penicillamine, who subsequently devel­
oped a neutrophilic agranulocytosis2. This article was not referenced 
because the Medline search covered the period 1966-1994. Jaffe’s main 
point is that D-penicillamine may also cause agranulocytosis sparing the 
eosinophilic lineage.
While we acknowledge this possibility, we have several comments on 
the Jaffe, el al article. First, both his patients were receiving longterm cor­
ticosteroid medication, which was withdrawn shortly before occurrence of 
the agranulocytosis. The withdrawal could have induced adrenal cortex 
insufficiency, which can be accompanied by eosinophilia.
Second, both patients developed pruritus shortly after and the 2nd 
patient also developed a rash after commencing the D-penicillamine. In the 
2nd patient the rash and eosinophilia appeared before agranulocytosis. 
These observations suggest drug hypersensitivity as cause of eosinophilia.
Third, the first patient showed no peripheral eosinophilia, while all our 
patients exhibited strong peripheral eosinophilia.
We do not know whether the pancytopenia associated with eosinophil­
ia is a specific MTX related phenomenon. What we do know, however, is 
that MTX continues to be a drug with surprising clinical effects, as has been 
shown, for instance, in the case of digital nodulosis1,
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Letters
Photochemotherapy for Refractory Rheumatoid Arthritis
To the Editor:
We read with interest the editorial by Dr. Haberman1 pointing out the use of 
photochemotherapy for the treatment of inflammatory arthritides, especial­
ly rheumatoid arthritis (RA), Extracorporeal photochemotherapy has been 
proposed in RA by Malawista1* and ourselves4*. Our procedure differs from 
that used by Malawista in that the enriched lymphocyte preparation is 
exposed ex vivo to 8-methoxypsoralen (8-MOP), in the presence of ultravi­
olet A (UVA). Oral ingestion of 8-MOP can be limited by the great varia­
tions of plasma final concentrations, and the total ex vivo procedure pro­
vides greater accuracy of lymphocyte irradiation. The technique reported 
by Laing, et al(' is indicated for the local treatment of affected joints, and 
could be limited by the problems of requiring repeated arthroscopies and 
also the inherent local dangers of UVA overexposure.
The excellent tolerance and the possibility of prolonged positive cffccts 
make extracorporeal photochemotherapy a therapeutic option in refractory 
RA. Photophoresis may be considered as an immunomodulatory treatment 
to ensure better general control of the disease.
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